CTAD 2025 1 - 4 December 2025

evoke and evoke+: Two phase 3 randomised placebo-controlled trials of semaglutide in participants with early-stage Alzheimer’s disease (NCT04777396 and NCT04777409)

Authors :

Jeffrey L. Cummings¹; Alireza Atri^2,3,4; Howard H. Feldman⁵; Mary Sano^6,7; Henrik Zetterberg⁸; Filip K. Knop⁹; Peter Johannsen⁹; Teresa León⁹; Rikke Mortensen Abschneider⁹; Philip Scheltens^10,11

Affiliations

View Details Hide Details

Keywords

Neurodegenerative diseases

Congress oral presentation

GLP-1 RA

Semaglutide (oral)

PHASE 3 (RCT)

Search Science Hub

Are you a healthcare professional?

evoke and evoke+: Two phase 3 randomised placebo-controlled trials of semaglutide in participants with early-stage Alzheimer’s disease (NCT04777396 and NCT04777409)